Dissolving stent could revolutionize heart disease treatment
NCT ID NCT05205499
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial is testing a new type of heart stent made from iron that slowly dissolves over time. The stent also releases a drug called sirolimus to help keep the artery open. About 1,059 people with coronary artery disease are receiving this device to see if it is safe and effective at treating blocked arteries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (a device that props open arteries and slowly releases a drug to prevent re-narrowing, then dissolves)
What this could lead to
If it works, this could offer a new treatment option for coronary artery disease that avoids permanent metal implants, potentially reducing long-term complications.
What could go wrong
This is a single-arm trial with no comparison group, so results may be less reliable. The scaffold might not dissolve as expected or could cause blood clots or other complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fuwai Yunnan Cardiovascular Hospital
Kunming, Yunnan, China